Use of U.S. Blood Donors for National Serosurveillance of SARS-CoV-2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program
Clicks: 145
ID: 265876
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
145 views
18 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #502 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AbstractIntroduction. The REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted month
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (17 words).
Try re-searching for a better abstract.
| Reference Key |
marsclinicaluse
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Stone, Mars;Di Germanio, Clara;Wright, David J;Sulaeman, Hasan;Dave, Honey;Fink, Rebecca V;Notari, Edward P;Green, Valerie;Strauss, Donna;Kessler, Debbie;Destree, Mark;Saa, Paula;Williamson, Phillip C;Simmons, Graham;Stramer, Susan L;Opsomer, Jean;Jones, Jefferson M;Kleinman, Steven;Busch, Michael P;NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P); |
| Journal | clinical infectious diseases |
| Year | Year not found |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.